
    
      Prospective, Randomized (3:2 active:control), Open Label, Event-driven Interventional Study.
      All subjects undergo the following: Baseline, Randomization, (Implantation & Optimization for
      subjects randomized to the active therapy), and Follow-up Period, followed by an Extension
      period, which lasts until the end of the study. The Clinical Events Committee (CEC) and Data
      Monitoring and Safety Board (DSMB) will conduct scheduled independent reviews of the data at
      the following time-points in order to ensure that an ongoing acceptable safety profile is
      being achieved.
    
  